CytomX News

CytomX Therapeutics Analyst Ratings

BenzingaMay 9 09:07 ET

Cautious Hold on CytomX Therapeutics Pending Comprehensive CX-904 Drug Data

TipRanksMay 9 06:43 ET

Barclays Sticks to Its Buy Rating for CytomX Therapeutics (CTMX)

TipRanksMay 9 03:26 ET

CytomX Therapeutics Analyst Ratings

BenzingaMay 6 08:33 ET

Jefferies Upgrades CytomX Therapeutics to Buy, Price Target at $8

MT NewswiresMay 6 07:09 ET

Analysts' Opinions Are Mixed on These Healthcare Stocks: Owens & Minor (OMI), Idexx Laboratories (IDXX) and CytomX Therapeutics (CTMX)

TipRanksMay 6 04:33 ET

Buy Rating for CytomX Therapeutics on Promising CX-904 Probody Therapy Prospects

TipRanksMay 5 19:55 ET

CytomX Therapeutics Analyst Ratings

BenzingaMay 1 12:09 ET

CytomX Therapeutics Analyst Ratings

BenzingaApr 22 08:17 ET

Analysts Offer Insights on Healthcare Companies: Cyclo Therapeutics (CYTH), CytomX Therapeutics (CTMX) and Pacific Biosciences (PACB)

TipRanksApr 22 04:20 ET

CytomX Therapeutics: A Balanced Hold Rating Amidst Financial Uncertainty and Clinical Progress

TipRanksMar 25 06:17 ET

J.P. Morgan Keeps Their Sell Rating on CytomX Therapeutics (CTMX)

TipRanksMar 12 06:05 ET

Analysts Have Conflicting Sentiments on These Healthcare Companies: Legend Biotech (LEGN), ACADIA Pharmaceuticals (ACAD) and CytomX Therapeutics (CTMX)

TipRanksMar 12 04:41 ET

Cautious Hold on CytomX Amid Awaiting Clinical Validation and Financial Outlook

TipRanksJan 9 01:17 ET

Analysts' Opinions Are Mixed on These Healthcare Stocks: CytomX Therapeutics (CTMX), BiomX (PHGE) and Moderna (MRNA)

TipRanksDec 1, 2023 06:30 ET

CytomX Therapeutics' Financial Outlook and Clinical Progress: An Analysis of the Hold Rating Decision

TipRanksNov 9, 2023 14:17 ET

Analysts Offer Insights on Healthcare Companies: CytomX Therapeutics (CTMX), Apyx Medical (APYX) and GoodRx Holdings (GDRX)

TipRanksNov 9, 2023 12:23 ET

CytomX Therapeutics Analyst Ratings

BenzingaNov 9, 2023 10:39 ET

Wedbush Upgrades CytomX Therapeutics to Outperform, Raises Price Target to $3

BenzingaNov 8, 2023 13:59 ET

CytomX Therapeutics Analyst Ratings

BenzingaNov 8, 2023 13:55 ET